The Impact of Hangeshashinto on Symptoms and Gut Microbiota in Diarrhea-type Irritable Bowel Syndrome: A Retrospective Analysis
Objectives: Effective treatments for diarrhea-type irritable bowel syndrome (IBS-D) are limited. Hangeshashinto (HST), an anti-inflammatory Kampo medicine, may offer benefits but its efficacy for IBS-D requires further investigation. This study evaluated IBS-D symptom improvement and gut microbiota...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Japan Society of Coloproctology
2025-01-01
|
| Series: | Journal of the Anus, Rectum and Colon |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/jarc/9/1/9_2024-068/_pdf/-char/en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584963074031616 |
|---|---|
| author | Naohisa Yoshida Takeshi Yasuda Yoshikazu Inagaki Daisuke Hasegawa Kohei Fukumoto Takaaki Murakami Ryohei Hirose Osamu Dohi Kazuhiko Uchiyama Tomohisa Takagi Yoshito Itoh |
| author_facet | Naohisa Yoshida Takeshi Yasuda Yoshikazu Inagaki Daisuke Hasegawa Kohei Fukumoto Takaaki Murakami Ryohei Hirose Osamu Dohi Kazuhiko Uchiyama Tomohisa Takagi Yoshito Itoh |
| author_sort | Naohisa Yoshida |
| collection | DOAJ |
| description | Objectives: Effective treatments for diarrhea-type irritable bowel syndrome (IBS-D) are limited. Hangeshashinto (HST), an anti-inflammatory Kampo medicine, may offer benefits but its efficacy for IBS-D requires further investigation. This study evaluated IBS-D symptom improvement and gut microbiota changes following HST administration.
Methods: This was a multicenter retrospective study with a prospective analysis of microbiota conducted at five affiliated institutions. Patients diagnosed with IBS-D based on the ROME IV criteria between April 2019 and December 2023, who received HST 7.5 g/day for 2-3 weeks were included. The outcome measures were improvement rates in overall symptoms, stool frequency, stool consistency, and abdominal pain. Intestinal microbiota was analyzed using 16S rRNA gene sequencing from fecal samples of 20 patients before and after HST treatment.
Results: One hundred patients (42 males/58 females, mean age: 69.5±11.8 years) were analyzed. The overall improvement rate of HST was 82.0%. Those of males and females were 81.0% and 82.8% (p=0.816). By age, those of patients aged 75 and aged <75 years were 82.9% and 81.5% (p=0.869). The improvement rates of stool frequency, stool consistency, and abdominal pain were 59.0%, 51.0%, and 62.0%, respectively. The stool frequency per week before and after HST was 21.7±18.2 vs. 14.0±12.6 (p<0.001). Significant differences in gut microbiota β diversity were observed, although α diversity was not significantly changed. Bacteroides (p=0.003) and Ruminococcus (p=0.010) decreased significantly, while Megasphaera (p=0.030) and Subdoligranulum (p=0.002) increased.
Conclusions: HST may improve IBS-D symptoms by altering microbiota composition. |
| format | Article |
| id | doaj-art-e1e170b2e0b84f4590d887d3ae4bff90 |
| institution | Kabale University |
| issn | 2432-3853 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | The Japan Society of Coloproctology |
| record_format | Article |
| series | Journal of the Anus, Rectum and Colon |
| spelling | doaj-art-e1e170b2e0b84f4590d887d3ae4bff902025-01-27T10:02:40ZengThe Japan Society of ColoproctologyJournal of the Anus, Rectum and Colon2432-38532025-01-019110511610.23922/jarc.2024-0682024-068The Impact of Hangeshashinto on Symptoms and Gut Microbiota in Diarrhea-type Irritable Bowel Syndrome: A Retrospective AnalysisNaohisa Yoshida0Takeshi Yasuda1Yoshikazu Inagaki2Daisuke Hasegawa3Kohei Fukumoto4Takaaki Murakami5Ryohei Hirose6Osamu Dohi7Kazuhiko Uchiyama8Tomohisa Takagi9Yoshito Itoh10Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical ScienceDepartment of Gastroenterology, Akashi City HospitalDepartment of Gastroenterology, Nishijin HospitalDepartment of Gastroenterology, Ayabe City HospitalDepartment of Gastroenterology, Saiseikai Suita HospitalDepartment of Gastroenterology, Aiseikai Yamashina HospitalDepartment of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical ScienceDepartment of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical ScienceDepartment of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical ScienceDepartment of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical ScienceDepartment of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical ScienceObjectives: Effective treatments for diarrhea-type irritable bowel syndrome (IBS-D) are limited. Hangeshashinto (HST), an anti-inflammatory Kampo medicine, may offer benefits but its efficacy for IBS-D requires further investigation. This study evaluated IBS-D symptom improvement and gut microbiota changes following HST administration. Methods: This was a multicenter retrospective study with a prospective analysis of microbiota conducted at five affiliated institutions. Patients diagnosed with IBS-D based on the ROME IV criteria between April 2019 and December 2023, who received HST 7.5 g/day for 2-3 weeks were included. The outcome measures were improvement rates in overall symptoms, stool frequency, stool consistency, and abdominal pain. Intestinal microbiota was analyzed using 16S rRNA gene sequencing from fecal samples of 20 patients before and after HST treatment. Results: One hundred patients (42 males/58 females, mean age: 69.5±11.8 years) were analyzed. The overall improvement rate of HST was 82.0%. Those of males and females were 81.0% and 82.8% (p=0.816). By age, those of patients aged 75 and aged <75 years were 82.9% and 81.5% (p=0.869). The improvement rates of stool frequency, stool consistency, and abdominal pain were 59.0%, 51.0%, and 62.0%, respectively. The stool frequency per week before and after HST was 21.7±18.2 vs. 14.0±12.6 (p<0.001). Significant differences in gut microbiota β diversity were observed, although α diversity was not significantly changed. Bacteroides (p=0.003) and Ruminococcus (p=0.010) decreased significantly, while Megasphaera (p=0.030) and Subdoligranulum (p=0.002) increased. Conclusions: HST may improve IBS-D symptoms by altering microbiota composition.https://www.jstage.jst.go.jp/article/jarc/9/1/9_2024-068/_pdf/-char/enirritable bowel syndromediarrheamicrobiotakampo medicine |
| spellingShingle | Naohisa Yoshida Takeshi Yasuda Yoshikazu Inagaki Daisuke Hasegawa Kohei Fukumoto Takaaki Murakami Ryohei Hirose Osamu Dohi Kazuhiko Uchiyama Tomohisa Takagi Yoshito Itoh The Impact of Hangeshashinto on Symptoms and Gut Microbiota in Diarrhea-type Irritable Bowel Syndrome: A Retrospective Analysis Journal of the Anus, Rectum and Colon irritable bowel syndrome diarrhea microbiota kampo medicine |
| title | The Impact of Hangeshashinto on Symptoms and Gut Microbiota in Diarrhea-type Irritable Bowel Syndrome: A Retrospective Analysis |
| title_full | The Impact of Hangeshashinto on Symptoms and Gut Microbiota in Diarrhea-type Irritable Bowel Syndrome: A Retrospective Analysis |
| title_fullStr | The Impact of Hangeshashinto on Symptoms and Gut Microbiota in Diarrhea-type Irritable Bowel Syndrome: A Retrospective Analysis |
| title_full_unstemmed | The Impact of Hangeshashinto on Symptoms and Gut Microbiota in Diarrhea-type Irritable Bowel Syndrome: A Retrospective Analysis |
| title_short | The Impact of Hangeshashinto on Symptoms and Gut Microbiota in Diarrhea-type Irritable Bowel Syndrome: A Retrospective Analysis |
| title_sort | impact of hangeshashinto on symptoms and gut microbiota in diarrhea type irritable bowel syndrome a retrospective analysis |
| topic | irritable bowel syndrome diarrhea microbiota kampo medicine |
| url | https://www.jstage.jst.go.jp/article/jarc/9/1/9_2024-068/_pdf/-char/en |
| work_keys_str_mv | AT naohisayoshida theimpactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT takeshiyasuda theimpactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT yoshikazuinagaki theimpactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT daisukehasegawa theimpactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT koheifukumoto theimpactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT takaakimurakami theimpactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT ryoheihirose theimpactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT osamudohi theimpactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT kazuhikouchiyama theimpactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT tomohisatakagi theimpactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT yoshitoitoh theimpactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT naohisayoshida impactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT takeshiyasuda impactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT yoshikazuinagaki impactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT daisukehasegawa impactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT koheifukumoto impactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT takaakimurakami impactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT ryoheihirose impactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT osamudohi impactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT kazuhikouchiyama impactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT tomohisatakagi impactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis AT yoshitoitoh impactofhangeshashintoonsymptomsandgutmicrobiotaindiarrheatypeirritablebowelsyndromearetrospectiveanalysis |